PTK2 and cancer: Combining FAK inhibitors with mTORC1 inhibitors to improve efficacy against drug-resistant cancers appears feasible (Shi et al., 2016; Liao et al., 2022; Qiao et al., 2022; Wang Z et al., 2022; Yang F et al., 2022), although further validation through clinical studies is necessary.